Skip to main content

NCT00088075 - A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


Data Specification

Available upon data request approval


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Risperidone
Product Name
RISPERDAL®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
160
% Female
36.0%
% White
53.0%
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
RIS-SCH-302/CR003370
Data Partner
Johnson & Johnson
Condition Studied
Schizophrenia
Mean/Median Age (Years)
16.0

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.